NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Vyne Therapeutics Inc. YARW
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$570,000
▲ 13.8% vs FY2024
EPS · FY25
$-0.62
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-66.3%
Net margin · FY25
-4646.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 570,000.00
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 4646 cents on every revenue dollar this year.
Profitability
-66.3%
Return on equity, FY2025
ROE
Operating margin-5219.1%
Net margin-4646.1%
Return on assets-54.6%
Each USD of equity lost 66 cents this year.
Growth
−51.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.1%
−51.4%
Compound annual rates per period — left blank where the series crosses a loss.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 30.2M
total assets, end of FY2025
Total assetsUSD 30.2M
EquityUSD 27.8M
CashUSD 24.0M
Gross debtUSD 0.00
Net debtUSD -24.0M
Current ratio12.53×
The company holds more cash than debt.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.3
−0.1
−0.1
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.62
−0.93
−2.78
−7.28
−25.64
−7.88
11.22
11.47
−5.69
−2.82
−0.97
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−66.3
−56.6
−47.4
−58.1
−170.3
−928.2
−173.4
−92.3
−148.5
·
·
Shares out B
0.03
0.01
0.01
0.00
0.00
0.04
0.01
0.02
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
The company
Identity as the company itself declares it to the SEC.
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015